Grant funding calls are often over-subscribed and success rates can be low. Excellent applications sometimes fail to be ...

As excitement builds around GLP-1s and their expanding list of potential indications, the conversation is shifting from hype ...

Pharma 4.0 is no longer a future ambition; it’s the baseline. The ability to operate with real-time data, integrated systems, ...

Vertex already has FDA approval for NaV1.8 inhibitor Journavx (suzetrigine) in acute pain, with late-stage trials on the go ...

The UK has started a 'world-first' gonorrhoea vaccination programme that is designed to prevent thousands of cases and save ...

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

EVERSANA – which is pharmaphorum's parent company – said that The AI Agency has been set up in collaboration with Google and draws on the tech giant's validated, compliant, and powerful AI, including ...

"For decades, bureaucrats and entrenched interests buried health data and blocked patients from taking control of their ...

Hemlibra (emicizumab), the only treatment currently available for haemophilia A via the NHS that doesn't require an ...

President Donald Trump has given leading pharma manufacturers a 60-day deadline to come up with a most favoured nation (MFN) ...

The results of the SURPASS-CVOT trial showed that dual GLP-1/GIP agonist Mounjaro (tirzepatide) was as effective as Lilly's ...

AbbVie already has a working relationship with Gilgamesh, in the form of an R&D collaboration and opt-in licensing agreement ...